While we may pursue an initial business combination opportunity in any industry or geographical location, we intend to capitalize on our management team’s background and experience to identify promising opportunities in the biotechnology sector.

  While we plan to evaluate opportunities in many sectors, we believe particularly attractive opportunities exist in the Diversified Industrial, Healthcare, Technology, Media and Telecom, and Alternative Asset Management sectors.

  While we may pursue an acquisition opportunity in any business industry or sector, we intend to capitalize on the ability of our management team to identify, acquire and manage a business in the consumer, healthcare and technology, media and telecommunications (“TMT”) industries that can benefit from our differentiated and proprietary deal flow, leading brand […]

  While we may pursue an initial business combination target in any stage of its corporate evolution in any industry, sector or geographic location (subject to certain limitations described in this prospectus), we intend to focus our search for a target business operating in North America in the automotive and automotive-related sector.

  Dun & Bradstreet is a leading global provider of business decisioning data and analytics. Our mission is to deliver a global network of trust, enabling clients to transform uncertainty into confidence, risk into opportunity and potential into prosperity. Clients embed our trusted, end-to-end solutions into their daily workflows to inform commercial credit decisions, confirm suppliers […]

  While we may pursue an acquisition in any business industry or sector, we intend to concentrate our efforts identifying businesses in the financial services industry with an enterprise value of approximately $750 million to $3 billion, with particular emphasis on businesses that are providing or changing technology for traditional financial services (“FinTech”), or those in the […]

  Lemonade is rebuilding insurance from the ground up on a digital substrate and an innovative business model. By leveraging technology, data, artificial intelligence, contemporary design and behavioral economics, we believe we are making insurance more delightful, more affordable, more precise and more socially impactful. To that end, we have built a vertically integrated company […]

  We are a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using our proprietary Polymer-Lipid Encapsulation matriX, or PLEX, technology. Our product candidates are designed to address diseases with high unmet medical needs by pairing our PLEX technology with drugs already approved by the U.S. Food and Drug Administration, […]

  We are a leading genomics company democratizing precision oncology. We offer a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. This empowers clinicians to control the sample, data, patient care and economics. Additionally, our products and services enable biopharmaceutical companies to cost-effectively accelerate drug development. We believe […]

  We are a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle […]